Make an Inquiry
Accelerating Influenza Drug Development

Influenza remains a persistent global health threat, driving the urgent need for innovative and effective therapeutic solutions. Ace Therapeutics is a specialized partner in preclinical drug development, dedicated exclusively to advancing Influenza therapeutics. Leveraging deep scientific expertise and state-of-the-art technologies, Ace Therapeutics delivers comprehensive preclinical solutions encompassing target validation, lead optimization, and IND-enabling studies. Our team integrates advanced virology platforms, robust in vitro and in vivo models, and rigorous data analytics to generate high-quality, translational results. With a strong foundation in regulatory compliance and up-to-date knowledge of global standards, Ace Therapeutics ensures that every program is positioned for seamless progression toward clinical development. By combining scientific rigor with operational excellence, Ace Therapeutics accelerates the path from discovery to first-in-human studies, empowering partners to address unmet needs in Influenza treatment. Ace Therapeutics is committed to driving therapeutic breakthroughs that improve patient outcomes and transform the landscape of Influenza care.

What is InfluenzaTargets for InfluenzaDrug Discovery and Development ServicesWhy Choose Us

What is Influenza

Influenza, commonly known as the flu, is an acute viral respiratory illness caused by influenza viruses of the Orthomyxoviridae family. The primary types affecting humans are influenza A and B, which are responsible for seasonal epidemics, while influenza A can also cause pandemics due to its genetic variability. The virus spreads mainly through inhalation of respiratory droplets, infecting the epithelial cells of the upper and lower respiratory tract. Viral replication initiates a strong immune response, including the release of pro-inflammatory cytokines, which contribute to the characteristic symptoms. Severe cases may result in complications such as viral pneumonia, secondary bacterial infections, or acute respiratory distress syndrome (ARDS), especially in vulnerable populations like the elderly, young children, pregnant women, and those with chronic illnesses. Clinically, influenza presents with sudden onset of fever, cough, sore throat, muscle aches, headache, and malaise. Diagnosis is based on clinical suspicion during periods of community transmission, supported by laboratory testing. The gold standard for confirmation is RT-PCR, which detects and subtypes influenza viruses with high sensitivity and specificity. Treatment options include antiviral drugs such as baloxavir marboxil, favipiravir, laninamivir octanoate, and peramivir, which inhibit viral replication or release. Annual vaccination remains the most effective preventive measure, reducing disease incidence and severity, especially in high-risk groups.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
img-2364589-86-4-suraxavir-marboxil suraxavir marboxil 2364589-86-4 C29 H25 F2 N3 O7 S 597.587
img-1985606-14-1-baloxavir-marboxil-rec-inn-usan baloxavir marboxil (Rec INN; USAN) 1985606-14-1 C27 H23 F2 N3 O7 S 571.549
img-259793-96-9-favipiravir-rec-inn-usan favipiravir (Rec INN; USAN) 259793-96-9 C5 H4 F N3 O2 157.103
influenza A (H1N1) monovalent vaccine
intradermal seasonal flu vaccine
img-203120-46-1-laninamivir-octanoate-prop-innm laninamivir octanoate (Prop INNM) 203120-46-1 C21 H36 N4 O8 472.533
img-unknown-peramivir-rec-inn-usan peramivir (Rec INN; USAN) C15 H28 N4 O4 328.407
pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)
influenza A (H1N1) 2009 Monovalent Vaccine

Learn More

Targets for Influenza

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
Influenza Virus Neuraminidase (Sialidase)
Human Influenza Virus M2 protein
RNA-Directed RNA Polymerase Catalytic Subunit (PB1)
Polymerase Acidic Protein
Matrix protein 2 M2
Membrane protein M2 M2
Matrix protein 2 M2
Matrix protein 2 M2
Hemagglutinin (viral)
Type II transmembrane glycoprotein; attachment glycoprotein that interacts directly with entry receptors

Influenza pathogenesis is driven by a set of well-characterized viral and host targets that orchestrate infection and immune response. Key among these are Hemagglutinin (HA), a viral surface glycoprotein responsible for binding to sialic acid receptors on host cells and mediating membrane fusion, and Matrix Protein 2 (M2), a proton channel critical for viral uncoating within the endosome. These viral proteins enable the virus to enter, replicate, and assemble within host cells. Additionally, host sensors such as Toll-Like Receptor 3 (TLR3) play a pivotal role in detecting viral double-stranded RNA and initiating innate immune responses, which are essential for controlling infection and shaping adaptive immunity.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates influenza drug discovery by providing robust screening and characterization platforms targeting viral proteins and host interactions. Utilizing biolayer interferometry, ELISA, and surface plasmon resonance assays, we deliver precise quantitative and qualitative data on key targets such as hemagglutinin and TLR3. Core parameters measured include IC-50 and Kd, supporting informed decision-making and rational lead selection. Comprehensive analytical support enables evaluation of binding affinity, inhibitory potency, and immune modulation, optimizing candidate selection and development. Our service ensures high-quality, data-driven insights for efficient advancement of antiviral therapies against influenza infection.

Hemagglutinin Hemagglutinin (H5)
Toll Like Receptor 3

Learn More

Why Choose Us

At Ace Therapeutics, we are dedicated to advancing the field of Influenza therapeutics through our specialized expertise and unwavering commitment to excellence. Our team comprises seasoned scientists and industry professionals with deep experience in Influenza research and drug development, ensuring that every project benefits from the highest level of knowledge and skill. We utilize advanced technology platforms and state-of-the-art laboratories, enabling us to deliver innovative solutions tailored to the unique challenges of Influenza drug discovery and development. Ace Therapeutics has established a strong track record of reliability and success in preclinical drug development services, consistently meeting client expectations and supporting the progression of promising therapeutics toward clinical evaluation. Our rigorous quality standards and strict adherence to regulatory guidelines ensure that all work is conducted with the utmost integrity and precision. Above all, Ace Therapeutics is committed to making a meaningful impact in the fight against Influenza by supporting our partners with the expertise and resources they need to bring new, effective treatments to patients worldwide. Choose Ace Therapeutics for professionalism, reliability, and a shared vision of a healthier future.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing new drugs for Influenza?

A: Preclinical research for Influenza faces several unique challenges, including the high mutation rate and antigenic variability of the Influenza virus, which can lead to rapid emergence of drug resistance. Additionally, appropriate selection and validation of animal models that accurately mimic human disease are critical but complex, as different strains can behave differently across species. At our company, we address these challenges by employing a broad panel of Influenza strains and validated animal models, ensuring robust evaluation of antiviral efficacy and resistance profiles.

Q: What are the key regulatory considerations for Influenza drug development in the preclinical stage?

A: Regulatory agencies such as the FDA and EMA require comprehensive data on pharmacodynamics, pharmacokinetics, and safety before advancing to clinical trials. For Influenza drugs, regulators may also expect demonstration of efficacy against multiple Influenza strains and subtypes. Our team is well-versed in global regulatory requirements and assists clients in designing preclinical studies that meet or exceed current guidelines, including GLP-compliant toxicology and efficacy assessments, to facilitate smooth IND/CTA submissions.

Q: What technical aspects are most critical in preclinical Influenza research?

A: Critical technical aspects include the selection of relevant viral strains, development of robust in vitro assays for viral replication and drug susceptibility, and the use of predictive in vivo models. Advanced molecular techniques, such as next-generation sequencing, are essential for monitoring viral mutations and resistance. Our company leverages state-of-the-art virology laboratories and experienced scientific staff to deliver high-quality, reproducible data across all technical aspects of Influenza research.

Q: What are the typical timeline and cost considerations for preclinical development of Influenza therapeutics?

A: Preclinical development for Influenza drugs generally takes 12-24 months, depending on the complexity of the compound and the breadth of required studies. Costs can vary widely, typically ranging from $2 million to $5 million for a full preclinical package, including efficacy, safety, and pharmacokinetic studies. We offer flexible, milestone-driven project plans and transparent pricing to help our clients manage budgets and timelines efficiently.

Q: What are the key success factors in preclinical Influenza drug development?

A: Success in preclinical Influenza drug development hinges on early identification of promising candidates with broad-spectrum activity, rigorous evaluation of resistance potential, and comprehensive safety profiling. Close alignment with regulatory expectations and proactive risk management are also crucial. Our company’s integrated approach, combining expert scientific guidance, regulatory support, and advanced technical capabilities, maximizes the likelihood of successful transition from preclinical to clinical development.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © Ace Therapeutics. All rights reserved.